COGT

Stats

Summary

unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act

Market Cap: 716 Million

Primary Exchange: NASDAQ

Website: unumrx.com

Shares Outstanding: 104 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.4335189263432118

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 772 trading days

From: 2015-07-16 To: 2020-12-01

Lowest Point: